{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:12:55Z","timestamp":1718763175031},"reference-count":181,"publisher":"IntechOpen","isbn-type":[{"value":"9781789852172","type":"print"},{"value":"9781789852189","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.5772\/intechopen.76931","type":"book-chapter","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T04:45:05Z","timestamp":1549514705000},"source":"Crossref","is-referenced-by-count":2,"title":["Angiogenesis and Antiangiogenesis in Multiple Myeloma"],"prefix":"10.5772","author":[{"given":"Roberto","family":"Ria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Melaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzurra","family":"Sportelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Kastrinakis NG, Gorgoulis VG, Foukas PG, et\u00a0al. Molecular aspects of multiple myeloma. Annals of Oncology. 2000;11:1217-1228. DOI: 10.1023\/A:1008331714186","DOI":"10.1023\/A:1008331714186"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Bergsagel PL, Chesi MV.\u00a0Molecular classification and risk stratification of myeloma. Hematological Oncology. 2013;31(Suppl 1):38-41. DOI: 10.1002\/hon.2065","DOI":"10.1002\/hon.2065"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Bhutani M, Landgren O, Usmani SZ.\u00a0Multiple myeloma: Is it time for biomarker-driven therapy? American Society of Clinical Oncology Educational Book. 2015:e493-e503. DOI: 10.14694\/EdBook_AM.2015.35.e493","DOI":"10.14694\/EdBook_AM.2015.35.e493"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Patel U, Luthra R, Medeiros LJ, Patel KP.\u00a0Diagnostic, prognostic, and predictive utility of recurrent somatic mutations in myeloid neoplasms. Clinical Lymphoma, Myeloma & Leukemia. 2017;17S:S62-S74. DOI: 10.1016\/j.clml.2017.02.015","DOI":"10.1016\/j.clml.2017.02.015"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Alzrigat M, P\u00e1rraga AA, Jernberg-Wiklund H.\u00a0Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology. 2017. (in press) pii: S1044-579X(17)30104-9. DOI: 10.1016\/j.semcancer.2017.09.007","DOI":"10.1016\/j.semcancer.2017.09.007"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA.\u00a0Hallmarks of cancer: The next generation. Cell. 2011;144:646-674. DOI: 10.1016\/j.cell.2011.02.013","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Langley RR, Fidler IJ.\u00a0Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocrine Reviews. 2007;28:297-321. DOI: 10.1210\/er.2006-0027","DOI":"10.1210\/er.2006-0027"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Amodio N, D'Aquila P, Passarino G, et\u00a0al. Epigenetic modifications in multiple myeloma: Recent advances on the role of DNA and histone methylation. Expert Opinion on Therapeutic Targets. 2017;21:91-101","DOI":"10.1080\/14728222.2016.1266339"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Glavey SV, Manier S, Sacco A, et\u00a0al. Epigenetics in multiple myeloma. Cancer Treatment and Research. 2016;169:35-49","DOI":"10.1007\/978-3-319-40320-5_4"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Zhan F, Huang Y, Colla S, et\u00a0al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028. DOI: 10.1182\/blood-2005-11-013458","DOI":"10.1182\/blood-2005-11-013458"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Ribatti D, Nico B, Vacca A.\u00a0Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis. International Review of Cell and Molecular Biology. 2015;314:259-282. DOI: 10.1016\/bs.ircmb.2014.10.004","DOI":"10.1016\/bs.ircmb.2014.10.004"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Mondello P, Cuzzocrea S, Navarra M, Mian M.\u00a0Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Oncotarget. 2017;8:20394-20409. DOI: 10.18632\/oncotarget.14610","DOI":"10.18632\/oncotarget.14610"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Ribatti D, Vacca A.\u00a0The role of microenvironment in tumor angiogenesis. Genes & Nutrition. 2008;3:29-34. DOI: 10.1007\/s12263-008-0076-3","DOI":"10.1007\/s12263-008-0076-3"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Ribatti D, Moschetta M, Vacca A.\u00a0Microenvironment and multiple myeloma spread. Thrombosis Research. 2014;133(Suppl 2):102-106. DOI: 10.1016\/S0049-3848(14)50017-5","DOI":"10.1016\/S0049-3848(14)50017-5"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Moschetta M, Kawano Y, Podar K.\u00a0Targeting the bone marrow microenvironment. Cancer Treatment and Research. 2016;169:63-102. DOI: 10.1007\/978-3-319-40320-5_6","DOI":"10.1007\/978-3-319-40320-5_6"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D, Roncali L, et\u00a0al. Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology. 1994;87:503-508. DOI: 10.1111\/j.1365-2141.1994.tb08304.x","DOI":"10.1111\/j.1365-2141.1994.tb08304.x"},{"key":"ref=17","unstructured":"Ria R, Reale A, De Luisi A, et\u00a0al. Bone marrow angiogenesis and progression in multiple myeloma. American Journal of Blood Research. 2011;1:76-89"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Stasi R, Amadori S.\u00a0The role of angiogenesis in hematologic malignancies. Journal of Hematotherapy & Stem Cell Research. 2002;11:49-68. DOI: 10.1089\/152581602753448531","DOI":"10.1089\/152581602753448531"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D.\u00a0Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20:193-199. DOI: 10.1038\/sj.leu.2404067","DOI":"10.1038\/sj.leu.2404067"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Vacca A, Ria R, Reale A, Ribatti D.\u00a0Angiogenesis in multiple myeloma. Chemical Immunology and Allergy. 2014;99:180-196. DOI: 10.1159\/000353312","DOI":"10.1159\/000353312"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D, Roccaro AM, et\u00a0al. Bone marrow angiogenesis in patients with active multiple myeloma. Seminars in Oncology. 2001;28:543-550","DOI":"10.1016\/S0093-7754(01)90022-3"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Asosingh K, De Raeve H, Menu E, et\u00a0al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: Role of CD45 heterogeneity. Blood. 2004;103:3131-3177. DOI: 10.1182\/blood-2003-08-2946","DOI":"10.1182\/blood-2003-08-2946"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Calcinotto A, Ponzoni M, Ria R, et\u00a0al. Modifications of the mouse bone marrow microenvironment favour angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Oncoimmunology. May 7, 2015;4(6):e1008850. eCollection Jun 2015. DOI: 10.1080\/2162402X.2015.1008850","DOI":"10.1080\/2162402X.2015.1008850"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Risau W, Flamme I.\u00a0Vasculogenesis. Annual Review of Cell and Developmental Biology. 1995;11:73-91. DOI: 10.1146\/annurev.cb.11.110195.000445","DOI":"10.1146\/annurev.cb.11.110195.000445"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Ribatti D.\u00a0Postnatal vasculogenesis. Mechanisms of Development. 2001;100:157-163. DOI: 10.1016\/S0925-4773(00)00522-0","DOI":"10.1016\/S0925-4773(00)00522-0"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Reale A, Melaccio A, Lamanuzzi A, et\u00a0al. Functional and biological role of endothelial precursor cells in tumour progression: A new potential therapeutic target in haematological malignancies. Stem Cells International. 2016;2016:7954580. DOI: 10.1155\/2016\/7954580","DOI":"10.1155\/2016\/7954580"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Moschetta M, Mishima Y, Sahin I, et\u00a0al. Role of endothelial progenitor cells in cancer progression. Biochimica et Biophysica Acta. 2014;1846:26-39. DOI: 10.1016\/j.bbcan.2014.03.005","DOI":"10.1016\/j.bbcan.2014.03.005"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Ria R, Piccoli C, Cirulli T, et\u00a0al. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clinical Cancer Research. 2008;14:1678-1685. DOI: 10.1158\/1078-0432.CCR-07-4071","DOI":"10.1158\/1078-0432.CCR-07-4071"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"D\u00f6me B, Hendrix MJ, Paku S, T\u00f3v\u00e1ri J, T\u00edm\u00e1r J.\u00a0Alternative vascularisation mechanisms in cancer: Pathology and therapeutic implications. The American Journal of Pathology. 2007;170:1-15. DOI: 10.2353\/ajpath.2007.060302","DOI":"10.2353\/ajpath.2007.060302"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Yang Z, Yao H, Fei F, et\u00a0al. Generation of erythroid cells from polyploid giant cancer cells: Re-thinking about tumor blood supply. Journal of Cancer Research and Clinical Oncology. 2018;144:617-627. DOI: 10.1007\/s00432-018-2598-4","DOI":"10.1007\/s00432-018-2598-4"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Pinto MP, Sotomayor P, Carrasco-Avino G, et\u00a0al. Escaping antiangiogenic therapy: Strategies employed by cancer cells. International Journal of Molecular Sciences. 2016;17:1489. pii: E1489. DOI: 10.3390\/ijms17091489","DOI":"10.3390\/ijms17091489"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D. Angiogenesis and vasculogenesis in multiple myeloma: Role of inflammatory cells. Recent Results in Cancer Research. 2011;183:187-195. DOI: 10.1007\/978-3-540-85772-3_4","DOI":"10.1007\/978-3-540-85772-3_4"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Rehman J, Li J, Orschell CM, March KL.\u00a0Peripheral blood \u201cendothelial progenitor cells\u201d are derived from monocyte\/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164-1169. DOI: 10.1161\/01.CIR.0000058702.69484.A0","DOI":"10.1161\/01.CIR.0000058702.69484.A0"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et\u00a0al. Multiple myeloma. Nature Reviews Disease Primers. 2017;3:17046. DOI: 10.1038\/nrdp.2017.46","DOI":"10.1038\/nrdp.2017.46"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Scavelli C, Nico B, Cirulli T, et\u00a0al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene. 2008;27:663-674. DOI: 10.1038\/sj.onc.1210691","DOI":"10.1038\/sj.onc.1210691"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Nico B, Mangieri D, Crivellato E, et\u00a0al. Mast Cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells and Development. 2008;17:19-22. DOI: 10.1089\/scd.2007.0132","DOI":"10.1089\/scd.2007.0132"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Manier S, Sacco A, Leleu X, et\u00a0al. Bone marrow microenvironment in multiple myeloma progression. Journal of Biomedicine & Biotechnology. 2012;2012:157496. DOI: 10.1155\/2012\/157496","DOI":"10.1155\/2012\/157496"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Vacca A, Ria R, Semeraro F, et\u00a0al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102:3340-3348. DOI: 10.1182\/blood-2003-04-1338","DOI":"10.1182\/blood-2003-04-1338"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Vacca A, Frigeri A, Ribatti D, et\u00a0al. Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. British Journal of Haematology. 2001;113:415-421. DOI: 10.1046\/j.1365-2141.2001.02738.x","DOI":"10.1046\/j.1365-2141.2001.02738.x"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Tenreiro MM, Correia ML, Brito MA.\u00a0Endothelial progenitor cells in multiple myeloma neovascularization: A brick to the wall. Angiogenesis. 2017;20:443-462. DOI: 10.1007\/s10456-017-9571-8","DOI":"10.1007\/s10456-017-9571-8"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Ria R, Todoerti K, Berardi S, et\u00a0al. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clinical Cancer Research. 2009;15:5369-5378. DOI: 10.1158\/1078-0432.CCR-09-0040","DOI":"10.1158\/1078-0432.CCR-09-0040"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Berardi S, Caivano A, Ria R, et\u00a0al. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene. 2012;31:2258-2269. DOI: 10.1038\/onc.2011.412. Epub Oct 3, 2011","DOI":"10.1038\/onc.2011.412"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Ribatti D, Vacca A.\u00a0Role of endothelial cells and fibroblasts in multiple myeloma angiogenic switch. Cancer Treatment and Research. 2016;169:51-61. DOI: 10.1007\/978-3-319-40320-5_5","DOI":"10.1007\/978-3-319-40320-5_5"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Franco OE, Shaw AK, Strand DW, Hayward SW.\u00a0Cancer associated fibroblasts in cancer pathogenesis. Seminars in Cell & Developmental Biology. 2010;21:33-39. DOI: 10.1016\/j.semcdb.2009.10.010","DOI":"10.1016\/j.semcdb.2009.10.010"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Santi A, Kugeratski FG, Zanivan S.\u00a0Cancer associated fibroblasts: The architects of stroma remodeling. Proteomics. 2018;18:e1700167. DOI: 10.1002\/pmic.201700167","DOI":"10.1002\/pmic.201700167"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Paulsson J, Micke P.\u00a0Prognostic relevance of cancer-associated fibroblasts in human cancer. Seminars in Cancer Biology. 2014;25:61-68. DOI: 10.1016\/j.semcancer.2014.02.006","DOI":"10.1016\/j.semcancer.2014.02.006"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Hinz B, Phan SH, Thannickal VJ, et\u00a0al. The myofibroblasts: One function, multiple origins. The American Journal of Pathology. 2007;170:1807-1816. DOI: 10.2353\/ajpath.2007.070112","DOI":"10.2353\/ajpath.2007.070112"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Frassanito MA, Rao L, Moschetta M, et\u00a0al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: In vitro and in\u00a0vivo studies. Leukemia. 2014;28:904-916. DOI: 10.1038\/leu.2013.254","DOI":"10.1038\/leu.2013.254"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Ribatti D, Vacca A. The role of inflammatory cells in angiogenesis in multiple myeloma. Advances in Experimental Medicine and Biology. 2014;816:361-376. DOI: 10.1007\/978-3-0348-0837-8_14","DOI":"10.1007\/978-3-0348-0837-8_14"},{"key":"ref=50","unstructured":"Salmi M.\u00a0Macrophages and cancer. Duodecim. 2017;133:829-837"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Kim J, Bae JS.\u00a0Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators of Inflammation. 2016;2016:6058147. DOI: 10.1155\/2016\/6058147","DOI":"10.1155\/2016\/6058147"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Barleon B, Sozzani S, Zhou D, et\u00a0al. Migration of human monocytes in response to vescular endothelial growth factor (VEGF) is mediated via the VEGF receptor Flt-1. Blood. 1996;87:3336-3343","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A.\u00a0Mast cell contribution to angiogenesis related to tumour progression. Clinical and Experimental Allergy. 2004;34:1660-1664. DOI: 10.1111\/j.1365-2222.2004.02104.x","DOI":"10.1111\/j.1365-2222.2004.02104.x"},{"key":"ref=54","unstructured":"S\u00f6rbo J, Jakobsson A, Norrby K.\u00a0Mast cell histamine is angiogenic through receptors for histamine 1 and histamine 2. International Journal of Experimental Pathology. 1994;75:43-50"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Thompson WD, Campbell R, Evans T.\u00a0Fibrin degradation and angiogenesis: Quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. The Journal of Pathology. 1995;145:27-37. DOI: 10.1002\/path.1711450103","DOI":"10.1002\/path.1711450103"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Ribatti D, Vacca A, Nico B, et\u00a0al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer. 1999;79:451-455. DOI: 10.1038\/sj.bjc.6690070","DOI":"10.1038\/sj.bjc.6690070"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Jurczyszyn A, Czepiel J, Gdula-Argasi\u0144ska J, et\u00a0al. The analysis of the relationship between multiple myeloma cells and their microenvironment. Journal of Cancer. 2015;6:160-168. DOI: 10.7150\/jca.10873","DOI":"10.7150\/jca.10873"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Giuliani N, Colla S, Morandi F, et\u00a0al. Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106:2472-2483. DOI: 10.1182\/blood-2004-12-4986","DOI":"10.1182\/blood-2004-12-4986"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R, et\u00a0al. The role of the Wnt-signaling antagonist DKK1\u00a0in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine. 2003;349:2483-2494. DOI: 10.1056\/NEJMoa030847","DOI":"10.1056\/NEJMoa030847"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Sun L, Iqbal J, Dolgilevich S, et\u00a0al. Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38\u00a0in bone resorption. The FASEB Journal. 2003;17:369-375. DOI: 10.1096\/fj.02-0205com","DOI":"10.1096\/fj.02-0205com"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"An G, Acharya C, Feng X, et\u00a0al. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: Therapeutic implication. Blood. 2016;128:1590-1603. DOI: 10.1182\/blood-2016-03-707547","DOI":"10.1182\/blood-2016-03-707547"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Horenstein AL, Quarona V, Toscani D, et\u00a0al. Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Molecular Medicine. 2016;22:694-704. DOI: 10.2119\/molmed.2016.00198","DOI":"10.2119\/molmed.2016.00198"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Costa F, Toscani D, Chillemi A, et\u00a0al. Expression of CD38\u00a0in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget. 2017;8:56598-56611. DOI: 10.18632\/oncotarget.17896","DOI":"10.18632\/oncotarget.17896"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Tamma R, Ribatti D.\u00a0Bone niches, hematopoietic stem cells, and vessel formation. International Journal of Molecular Sciences. 2017;18:1-13. pii: E151. DOI: 10.3390\/ijms18010151","DOI":"10.3390\/ijms18010151"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Birbrair A, Frenette PS.\u00a0Niche heterogeneity in the bone marrow. Annals of the New\u00a0York Academy of Sciences. 2016;1370:82-96. DOI: 10.1111\/nyas.13016","DOI":"10.1111\/nyas.13016"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Bhaskar A, Gupta R, Kumar L, et\u00a0al. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leukemia & Lymphoma. 2012;53:635-640. DOI: 10.3109\/10428194.2011.628880","DOI":"10.3109\/10428194.2011.628880"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Zhang H, Vakil V, Braunstein M, et\u00a0al. Circulating endothelial progenitor cells in multiple myeloma: Implications and significance. Blood. 2005;105:3286-3294. DOI: 10.1182\/blood-2004-06-2101","DOI":"10.1182\/blood-2004-06-2101"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Wang L, Du F, Zhang HM, et\u00a0al. Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone. Brazilian Journal of Medical and Biological Research. 2015;48:736-742. DOI: 10.1590\/1414-431X20154558","DOI":"10.1590\/1414-431X20154558"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Rigolin GM, Fraulini C, Ciccone M, et\u00a0al. Neoplastic circulating endothelial cells in multiple myeloma 13q14 deletion. Blood. 2006;107:2531-2535","DOI":"10.1182\/blood-2005-04-1768"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Xu S, De Veirman K, De Becker A, et\u00a0al. Mesenchymal stem cells in multiple myeloma: A therapeutical tool or target? Leukemia. 2018. (in press) DOI: 10.1038\/s41375-018-0061-9","DOI":"10.1038\/s41375-018-0061-9"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Reagan MR, Ghobrial IM.\u00a0Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. Clinical Cancer Research. 2012;18:342-349. DOI: 10.1158\/1078-0432.CCR-11-2212","DOI":"10.1158\/1078-0432.CCR-11-2212"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Herrero C, P\u00e9rez-Sim\u00f3n JA.\u00a0Immunomodulatory effect of mesenchymal stem cells. Brazilian Journal of Medical and Biological Research. 2010;43:425-430","DOI":"10.1590\/S0100-879X2010007500033"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Markovina S, Callander NS, O'Connor SL, et\u00a0al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Molecular Cancer. 2010;9:176. DOI: 10.1186\/1476-4598-9-176","DOI":"10.1186\/1476-4598-9-176"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Hao M, Zhang L, An G, et\u00a0al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leukemia & Lymphoma. 2011;52:1787-1794. DOI: 10.3109\/10428194.2011.576791","DOI":"10.3109\/10428194.2011.576791"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Garcia-Gomez A, Sanchez-Guijo F, Del Ca\u00f1izo MC, et\u00a0al. Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World Journal of Stem Cells. 2014;6:322-343. DOI: 10.4252\/wjsc.v6.i3.322","DOI":"10.4252\/wjsc.v6.i3.322"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Soukas A, Socci ND, Saatkamp BD, et\u00a0al. Distinct transcriptional profiles of adipogenesis in\u00a0vivo and in\u00a0vitro. The Journal of Biological Chemistry. 2001;276:34167-34174. DOI: 10.1074\/jbc.M104421200","DOI":"10.1074\/jbc.M104421200"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Baek JH, Jang JE, Kang CM, et\u00a0al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000;19:4621-4631. DOI: 10.1038\/sj.onc.1203814","DOI":"10.1038\/sj.onc.1203814"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Cozzo AJ, Fuller AM, Makowski L.\u00a0Contribution of adipose tissue to development of cancer. Comprehensive Physiology. 2017;8:237-282. DOI: 10.1002\/cphy.c170008","DOI":"10.1002\/cphy.c170008"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Wagner M, Dudley AC.\u00a0A three-party alliance in solid tumors: Adipocytes, macrophages and vascular endothelial cells. Adipocytes. 2013;2:67-73. DOI: 10.4161\/adip.23016","DOI":"10.4161\/adip.23016"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Nieman KM, Romero IL, Van Houten B, Lengyel E.\u00a0Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochimica et Biophysica Acta. 2013;1831:1533-1541. DOI: 10.1016\/j.bbalip.2013.02.010","DOI":"10.1016\/j.bbalip.2013.02.010"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Falank C, Fairfield H, Reagan MR.\u00a0Signaling interplay between bone marrow adipose tissue and multiple myeloma cells. Frontiers in Endocrinology (Lausanne). 2016;7:67. DOI: 10.3389\/fendo.2016.00067","DOI":"10.3389\/fendo.2016.00067"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Spencer JA, Ferraro F, Roussakis E, et\u00a0al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508:269-273. DOI: 10.1038\/nature13034","DOI":"10.1038\/nature13034"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Kakudo N, Morimoto N, Ogawa T, et\u00a0al. Hypoxia enhances proliferation of human adipose-derived stem cells via HIF-1\u03b1 activation. PLoS One. 2015;10:e0139890. DOI: 10.1371\/journal.pone.0139890","DOI":"10.1371\/journal.pone.0139890"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Baeriswyl V, Christofori G.\u00a0The angiogenic switch in carcinogenesis. Seminars in Cancer Biology. Oct 2009;19(5):329-337. DOI: 10.1016\/j.semcancer.2009.05.003","DOI":"10.1016\/j.semcancer.2009.05.003"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"Kazerounian S, Lawler J.\u00a0Integration of pro- and anti-angiogenic signals by endothelial cells. Journal of Cell Communication and Signaling. 2018;12:171-179. DOI: 10.1007\/s12079-017-0433-3","DOI":"10.1007\/s12079-017-0433-3"},{"key":"ref=86","doi-asserted-by":"crossref","unstructured":"Ria R, Roccaro AM, Merchionne F, et\u00a0al. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003;17:1961-1966. DOI: 10.1038\/sj.leu.2403076","DOI":"10.1038\/sj.leu.2403076"},{"key":"ref=87","doi-asserted-by":"crossref","unstructured":"Ramakrishnan V, D'Souza A.\u00a0Signaling pathways and emerging therapies in multiple myeloma. Current Hematologic Malignancy Reports. Apr 2016;11(2):156-164. DOI: 10.1007\/s11899-016-0315-4","DOI":"10.1007\/s11899-016-0315-4"},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Medinger M, Passweg J.\u00a0Role of tumour angiogenesis in haematological malignancies. Swiss Medical Weekly. Nov 6, 2014;144:w14050. DOI: 10.4414\/smw.2014.14050","DOI":"10.4414\/smw.2014.14050"},{"key":"ref=89","unstructured":"Vacca A, Ria R, Ribatti D, et\u00a0al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88:176-185"},{"key":"ref=90","doi-asserted-by":"crossref","unstructured":"Ria R, Vacca A, Russo F, et\u00a0al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thrombosis and Haemostasis. 2004;93:1438-1445. DOI: 10.1160\/TH04-06-0334","DOI":"10.1160\/TH04-06-0334"},{"key":"ref=91","doi-asserted-by":"crossref","unstructured":"Dankbar B, Padro T, Leo R, et\u00a0al. Vascular endothelial growth factor and interleukin-6\u00a0in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636","DOI":"10.1182\/blood.V95.8.2630"},{"key":"ref=92","doi-asserted-by":"crossref","unstructured":"Vacca A, Ribatti D, Presta M, et\u00a0al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073","DOI":"10.1182\/blood.V93.9.3064"},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Suvannasankha A, Tompkins DR, Edwards DF, et\u00a0al. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 2015;6:19647-19660. DOI: 10.18632\/oncotarget.3794","DOI":"10.18632\/oncotarget.3794"},{"key":"ref=94","doi-asserted-by":"crossref","unstructured":"Sucak GT, Aki SZ, Y\u00fczba\u015fio\u011flu B, et\u00a0al. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leukemia & Lymphoma. 2011;52:1281-1289. DOI: 10.3109\/10428194.2011.569695","DOI":"10.3109\/10428194.2011.569695"},{"key":"ref=95","doi-asserted-by":"crossref","unstructured":"Bisping G, Leo R, Wenning D, et\u00a0al. Paracrine interactions of basic fibroblast growth factor and interleukin-6\u00a0in multiple myeloma. Blood. 2003;101:2775-2783. DOI: 10.1182\/blood-2002-09-2907","DOI":"10.1182\/blood-2002-09-2907"},{"key":"ref=96","doi-asserted-by":"crossref","unstructured":"Witzig T, Kimlinger T, Stenson M, Thereneau T.\u00a0Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma. 1998;31:167-175. DOI: 10.3109\/10428199809057596","DOI":"10.3109\/10428199809057596"},{"key":"ref=97","doi-asserted-by":"crossref","unstructured":"Basile A, Moschetta M, Ditonno P, et\u00a0al. Pentraxin 3 (PTX3) inhibits plasma cell\/stromal cell cross-talk in the bone marrow of multiple myeloma patients. The Journal of Pathology. 2013;229:87-98. DOI: 10.1002\/path.4081","DOI":"10.1002\/path.4081"},{"key":"ref=98","doi-asserted-by":"crossref","unstructured":"Yamamoto S, Hagihara T, Horiuchi Y, et\u00a0al. Mediator cyclin-dependent kinases upregulate transcription of inflammatory genes in cooperation with NF-\u03baB and C\/EBP\u03b2 on stimulation of toll-like receptor 9. Genes to Cells. 2017;22:265-276. DOI: 10.1111\/gtc.12475","DOI":"10.1111\/gtc.12475"},{"key":"ref=99","doi-asserted-by":"crossref","unstructured":"Ferrucci A, Moschetta M, Frassanito MA, et\u00a0al. A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clinical Cancer Research. 2014;20:5796-5807. DOI: 10.1158\/1078-0432.CCR-14-0847","DOI":"10.1158\/1078-0432.CCR-14-0847"},{"key":"ref=100","doi-asserted-by":"crossref","unstructured":"Gambella M, Palumbo A, Rocci A.\u00a0MET\/HGF pathway in multiple myeloma: From diagnosis to targeted therapy? Expert Review of Molecular Diagnostics. 2015;15:881-893. DOI: 10.1586\/14737159.2015.1046436","DOI":"10.1586\/14737159.2015.1046436"},{"key":"ref=101","doi-asserted-by":"crossref","unstructured":"Jurczyszyn A, Zebzda A, Gdula-Argasi\u0144ska J, et\u00a0al. Blocking MET receptor signaling in multiple myeloma cells in\u00a0vitro and in\u00a0vivo. Advances in Clinical and Experimental Medicine. 2018;27:153-158. DOI: 10.17219\/acem\/68271","DOI":"10.17219\/acem\/68271"},{"key":"ref=102","doi-asserted-by":"crossref","unstructured":"Ting KR, Henry M, Meiller J, et\u00a0al. Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients. BBA Clinical. 2017;8:28-34. DOI: 10.1016\/j.bbacli.2017.05.003","DOI":"10.1016\/j.bbacli.2017.05.003"},{"key":"ref=103","doi-asserted-by":"crossref","unstructured":"Belloni D, Marcatti M, Ponzoni M, et\u00a0al. Angiopoietin-2\u00a0in bone marrow milieu promotes multiple myeloma-associated angiogenesis. Experimental Cell Research. 2015;330:1-12. DOI: 10.1016\/j.yexcr.2014.10.017","DOI":"10.1016\/j.yexcr.2014.10.017"},{"key":"ref=104","doi-asserted-by":"crossref","unstructured":"Giuliani N, Colla S, Lazzaretti M, et\u00a0al. Proangiogenic properties of human myeloma cells: Production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 2003;102:638-645. DOI: 10.1182\/blood-2002-10-3257","DOI":"10.1182\/blood-2002-10-3257"},{"key":"ref=105","doi-asserted-by":"crossref","unstructured":"Pappa CA, Tsirakis G, Samiotakis P, et\u00a0al. Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma. Cancer Investigation. 2013;31:385-389. DOI: 10.3109\/07357907.2013.800093","DOI":"10.3109\/07357907.2013.800093"},{"key":"ref=106","doi-asserted-by":"crossref","unstructured":"Terpos E, Anargyrou K, Katodritou E, et\u00a0al. Greek myeloma study group, Greece. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. International Journal of Cancer. 2012;130:735-742. DOI: 10.1002\/ijc.26062","DOI":"10.1002\/ijc.26062"},{"key":"ref=107","doi-asserted-by":"crossref","unstructured":"Cheriyath V, Husein MA.\u00a0Osteopontin, angiogenesis and multiple myeloma. Leukemia. 2005;19:2203-2205. DOI: 10.1038\/sj.leu.2403978","DOI":"10.1038\/sj.leu.2403978"},{"key":"ref=108","doi-asserted-by":"crossref","unstructured":"Babarovi\u0107 E, Valkovi\u0107 T, Budisavljevi\u0107 I, et\u00a0al. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma. Pathology, Research and Practice. 2016;212:509-516. DOI: 10.1016\/j.prp.2015.11.021","DOI":"10.1016\/j.prp.2015.11.021"},{"key":"ref=109","doi-asserted-by":"crossref","unstructured":"Sfiridaki A, Miyakis S, Pappa C, et\u00a0al. Circulating osteopontin: A dual marker of bone destruction and angiogenesis in patients with multiple myeloma. Journal of Hematology & Oncology. 2011;4:22. DOI: 10.1186\/1756-8722-4-22","DOI":"10.1186\/1756-8722-4-22"},{"key":"ref=110","doi-asserted-by":"crossref","unstructured":"Bolkun L, Lemancewicz D, Sobolewski K, et\u00a0al. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment. Advances in Medical Sciences. 2013;58:118-125. DOI: 10.2478\/v10039-012-0048-0","DOI":"10.2478\/v10039-012-0048-0"},{"key":"ref=111","unstructured":"Bilalis A, Pouliou E, Roussou M, et\u00a0al. Increased expression of platelet derived growth factor receptor \u03b2 on trephine biopsies correlates with advanced myeloma. Journal of Balkan Union of Oncology. 2017;22:1032-1037"},{"key":"ref=112","doi-asserted-by":"crossref","unstructured":"Barill\u00e9 S, Akhoundi C, Collette M, et\u00a0al. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of pro MMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997;90:1649-1655","DOI":"10.1182\/blood.V90.4.1649"},{"key":"ref=113","doi-asserted-by":"crossref","unstructured":"Coluccia AML, Cirulli T, Neri P, et\u00a0al. Validation of PDGFR\u03b2 and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: Preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood. 2008;12:1346-1356. DOI: 10.1182\/blood-2007-10-116590","DOI":"10.1182\/blood-2007-10-116590"},{"key":"ref=114","doi-asserted-by":"crossref","unstructured":"Tsirakis G, Pappa CA, Kanellou P, et\u00a0al. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma. Hematological Oncology. 2012;30:131-136. DOI: 10.1002\/hon.1014","DOI":"10.1002\/hon.1014"},{"key":"ref=115","doi-asserted-by":"crossref","unstructured":"Airoldi I, Cocco C, Giuliani N, et\u00a0al. Constitutive expression of IL-12Rb2 on human multiple myeloma cells delineates a novel therapeutic target. Blood. 2008;112:750-759. DOI: 10.1182\/blood-2008-02-139378","DOI":"10.1182\/blood-2008-02-139378"},{"key":"ref=116","doi-asserted-by":"crossref","unstructured":"Cocco C, Giuliani N, Di Carlo E, et\u00a0al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clinical Cancer Research. 2010;16:4188-4197. DOI: 10.1158\/1078-0432.CCR-10-0173","DOI":"10.1158\/1078-0432.CCR-10-0173"},{"key":"ref=117","doi-asserted-by":"crossref","unstructured":"Dondero A, Casu B, Bellora F, et\u00a0al. NK cells and multiple myeloma-associated endothelial cells: Molecular interactions and influence of IL-27. Oncotarget. 2017;8:35088-35102. DOI: 10.18632\/oncotarget.17070","DOI":"10.18632\/oncotarget.17070"},{"key":"ref=118","doi-asserted-by":"crossref","unstructured":"Pellegrino A, Ria R, Di Pietro G, et\u00a0al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. British Journal of Haematology. 2005;129:248-256. DOI: 10.1111\/j.1365-2141.2005.05443.x","DOI":"10.1111\/j.1365-2141.2005.05443.x"},{"key":"ref=119","doi-asserted-by":"crossref","unstructured":"Colla S, Storti P, Donofrio G, et\u00a0al. Low bone marrow oxygen tension and hypoxia-inducible factor-1\u03b1 overexpression characterize patients with multiple myeloma: Role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24:1967-1970. DOI: 10.1038\/leu.2010.193","DOI":"10.1038\/leu.2010.193"},{"key":"ref=120","doi-asserted-by":"crossref","unstructured":"Pappa CA, Tsirakis G, Kanellou P, et\u00a0al. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine. 2011;56:616-620. DOI: 10.1016\/j.cyto.2011.08.034","DOI":"10.1016\/j.cyto.2011.08.034"},{"key":"ref=121","unstructured":"Bhaskar A, Tiwary BN.\u00a0Hypoxia inducible factor-1 alpha and multiple myeloma. International Journal of Advanced Research (Indore). 2016;4:706-715"},{"key":"ref=122","doi-asserted-by":"crossref","unstructured":"Zhang J, Sattler M, Tonon G, et\u00a0al. Targeting angiogenesis via a c-Myc\/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Research. 2009;69:5082-5090. DOI: 10.1158\/0008-5472.CAN-08-4603","DOI":"10.1158\/0008-5472.CAN-08-4603"},{"key":"ref=123","doi-asserted-by":"crossref","unstructured":"Borsi E, Perrone G, Terragna C, et\u00a0al. HIF-1\u03b1 inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Experimental Cell Research. 2014;328:444-455. DOI: 10.1016\/j.yexcr.2014.09.018","DOI":"10.1016\/j.yexcr.2014.09.018"},{"key":"ref=124","doi-asserted-by":"crossref","unstructured":"Ria R, Catacchio I, Berardi S, et\u00a0al. HIF-1\u03b1 of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clinical Cancer Research. 2014;20:847-858. DOI: 10.1158\/1078-0432.CCR-13-1950","DOI":"10.1158\/1078-0432.CCR-13-1950"},{"key":"ref=125","doi-asserted-by":"crossref","unstructured":"Conciatori F, Ciuffreda L, Bazzichetto C, et\u00a0al. mTOR cross-talk in cancer and potential for combination therapy. Cancers (Basel). 2018;10:1-30. pii: E23. DOI: 10.3390\/cancers10010023","DOI":"10.3390\/cancers10010023"},{"key":"ref=126","doi-asserted-by":"crossref","unstructured":"Janku F, Yap TA, Meric-Bernstam F.\u00a0Targeting the PI3K pathway in cancer: Are we making headway? Nature Reviews. Clinical Oncology. 2018;15:273-291. DOI: 10.1038\/nrclinonc.2018.28","DOI":"10.1038\/nrclinonc.2018.28"},{"key":"ref=127","doi-asserted-by":"crossref","unstructured":"Lamanuzzi A, Saltarella I, Desantis V, et\u00a0al. Inhibition of mTOR Complex 2 Restrains Tumor Angiogenesis in Multiple Myeloma Oncotarget. 2018 (in press)","DOI":"10.18632\/oncotarget.25003"},{"key":"ref=128","doi-asserted-by":"crossref","unstructured":"LaFoya B, Munroe JA, Mia MM, et\u00a0al. Notch: A multi-functional integrating system of microenvironmental signals. Developmental Biology. 2016;418:227-241. DOI: 10.1016\/j.ydbio.2016.08.023","DOI":"10.1016\/j.ydbio.2016.08.023"},{"key":"ref=129","doi-asserted-by":"crossref","unstructured":"Colombo M, Mirandola L, Platonova N, et\u00a0al. Notch-directed microenvironment reprogramming in myeloma: A single path to multiple outcomes. Leukemia. 2013;27:1009-1018. DOI: 10.1038\/leu.2013.6","DOI":"10.1038\/leu.2013.6"},{"key":"ref=130","doi-asserted-by":"crossref","unstructured":"Pasquale EB.\u00a0Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nature Reviews. Cancer. 2010;10:165-180. DOI: 10.1038\/nrc2806","DOI":"10.1038\/nrc2806"},{"key":"ref=131","doi-asserted-by":"crossref","unstructured":"Feldheim DA, O\u2019Leary DD.\u00a0Visual map development: Bidirectional signaling, bifunctional guidance molecules, and competition. Cold Spring Harbor Perspectives in Biology. 2010;2:a001768-a001768. DOI: 10.1101\/cshperspect.a001768","DOI":"10.1101\/cshperspect.a001768"},{"key":"ref=132","doi-asserted-by":"crossref","unstructured":"Janes PW, Slape CI, Farnsworth RH, et\u00a0al. EphA3 biology and cancer. Growth Factors. 2014;32:176-189. DOI: 10.3109\/08977194.2014.982276","DOI":"10.3109\/08977194.2014.982276"},{"key":"ref=133","doi-asserted-by":"crossref","unstructured":"Brantley DM, Cheng N, Thompson EJ, et\u00a0al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002;21:7011-7026. DOI: 10.1038\/sj.onc.1205679","DOI":"10.1038\/sj.onc.1205679"},{"key":"ref=134","doi-asserted-by":"crossref","unstructured":"Caivano A, La Rocca F, Laurenzana I, et\u00a0al. Epha3 acts as proangiogenic factor in multiple myeloma. Oncotarget. 2017;8:34298-34309. DOI: 10.18632\/oncotarget.16100","DOI":"10.18632\/oncotarget.16100"},{"key":"ref=135","doi-asserted-by":"crossref","unstructured":"Lechertier T, Hodivala-Dilke K.\u00a0Focal adhesion kinase and tumour angiogenesis. The Journal of Pathology. 2012;226:404-412. DOI: 10.1002\/path.3018","DOI":"10.1002\/path.3018"},{"key":"ref=136","doi-asserted-by":"crossref","unstructured":"Coelho NM, Llopis-Hern\u00e1ndez V, Salmer\u00f3n-S\u00e1nchez M, Altankov G.\u00a0Dynamic reorganization and enzymatic remodeling of type IV collagen at cell-biomaterial Interface. Advances in Protein Chemistry and Structural Biology. 2016;105:81-104. DOI: 10.1016\/bs.apcsb.2016.06.001","DOI":"10.1016\/bs.apcsb.2016.06.001"},{"key":"ref=137","doi-asserted-by":"crossref","unstructured":"Infusino GA, Jacobson JR.\u00a0Endothelial FAK as a therapeutic target in disease. Microvascular Research. 2012;83:89-96. DOI: 10.1016\/j.mvr.2011.09.011","DOI":"10.1016\/j.mvr.2011.09.011"},{"key":"ref=138","doi-asserted-by":"crossref","unstructured":"Tanghetti E, Ria R, Dell'Era P, et\u00a0al. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): Recruitment of FGF receptor-1\u00a0in endothelial cell adhesion contacts. Oncogene. 2002;21:3889-3897. DOI: 10.1038\/sj.onc.1205407","DOI":"10.1038\/sj.onc.1205407"},{"key":"ref=139","doi-asserted-by":"crossref","unstructured":"Masoud GN, Li W.\u00a0HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5:378-389. DOI: 10.1016\/j.apsb.2015.05.007","DOI":"10.1016\/j.apsb.2015.05.007"},{"key":"ref=140","doi-asserted-by":"crossref","unstructured":"Sang N, Stiehl DP, Bohensky J, et\u00a0al. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. The Journal of Biological Chemistry. 2003;278:14013-14019. DOI: 10.1074\/jbc.M209702200","DOI":"10.1074\/jbc.M209702200"},{"key":"ref=141","doi-asserted-by":"crossref","unstructured":"Bartel DP.\u00a0MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"ref=142","doi-asserted-by":"crossref","unstructured":"Winter J, Diederichs S.\u00a0MicroRNA biogenesis and cancer. Methods in Molecular Biology. 2011;676:3-22. DOI: 10.1007\/978-1-60761-863-8_1","DOI":"10.1007\/978-1-60761-863-8_1"},{"key":"ref=143","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang L, Chen C, Chu X.\u00a0New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Molecular Cancer. 2018;17:22. DOI: 10.1186\/s12943-018-0766-4","DOI":"10.1186\/s12943-018-0766-4"},{"key":"ref=144","doi-asserted-by":"crossref","unstructured":"Wang W, Zhang E, Lin C.\u00a0MicroRNAs in tumor angiogenesis. Life Sciences. 2015;136:28-35. DOI: 10.1016\/j.lfs.2015.06.025","DOI":"10.1016\/j.lfs.2015.06.025"},{"key":"ref=145","doi-asserted-by":"crossref","unstructured":"Yin R, Guo L, Zhang W, Zheng J.\u00a0The pleiotropic effects of miRNAs on tumor angiogenesis. Journal of Cellular Biochemistry. 2015;116:1807-1815. DOI: 10.1002\/jcb.24679","DOI":"10.1002\/jcb.24679"},{"key":"ref=146","doi-asserted-by":"crossref","unstructured":"Ohyashiki JH, Umezu T, Ohyashiki K.\u00a0Exosomes promote bone marrow angiogenesis in hematologic neoplasia: The role of hypoxia. Current Opinion in Hematology. 2016;23:268-273. DOI: 10.1097\/MOH.0000000000000235","DOI":"10.1097\/MOH.0000000000000235"},{"key":"ref=147","doi-asserted-by":"crossref","unstructured":"Umezu T, Tadokoro H, Azuma K, et\u00a0al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124:3748-3757. DOI: 10.1182\/blood-2014-05-576116","DOI":"10.1182\/blood-2014-05-576116"},{"key":"ref=148","doi-asserted-by":"crossref","unstructured":"Raimondi L, Amodio N, Di Martino MT, et\u00a0al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in\u00a0vivo anti-tumor activity. Oncotarget. 2014;5:3039-3054. DOI: 10.18632\/oncotarget.1747","DOI":"10.18632\/oncotarget.1747"},{"key":"ref=149","doi-asserted-by":"crossref","unstructured":"Sun CY, She XM, Qin Y, et\u00a0al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.\u00a0Carcinogenesis. 2013;34:426-435. DOI: 10.1093\/carcin\/bgs333","DOI":"10.1093\/carcin\/bgs333"},{"key":"ref=150","doi-asserted-by":"crossref","unstructured":"Katoh M.\u00a0Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (review). International Journal of Molecular Medicine. 2013;32:763-767. DOI: 10.3892\/ijmm.2013.1444","DOI":"10.3892\/ijmm.2013.1444"},{"key":"ref=151","doi-asserted-by":"crossref","unstructured":"Ria R, Reale A, Vacca A.\u00a0Novel agents and new therapeutic approaches for treatment of multiple myeloma. World Journal of Methodology. 2014;4:73-90. DOI: 10.5662\/wjm.v4.i2.73","DOI":"10.5662\/wjm.v4.i2.73"},{"key":"ref=152","doi-asserted-by":"crossref","unstructured":"Barchnicka A, Olejniczak-Nowakowska M, Krupa-Kotara K, Grosicki S.\u00a0The importance of antiangiogenic effect in multiple myeloma treatment. Advances in Clinical and Experimental Medicine. 2018;27:291-297. DOI: 10.17219\/acem\/68826","DOI":"10.17219\/acem\/68826"},{"key":"ref=153","doi-asserted-by":"crossref","unstructured":"Kumar S.\u00a0Emerging options in multiple myeloma: Targeted, immune, and epigenetic therapies. Hematology. American Society of Hematology. Education Program. 2017;2017:518-524. DOI: 10.1182\/asheducation-2017.1.518","DOI":"10.1182\/asheducation-2017.1.518"},{"key":"ref=154","doi-asserted-by":"crossref","unstructured":"Roccaro AM, Hideshima T, Raje N, et\u00a0al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research. 2006;66:184-191. DOI: 10.1158\/0008-5472.CAN-05-1195","DOI":"10.1158\/0008-5472.CAN-05-1195"},{"key":"ref=155","doi-asserted-by":"crossref","unstructured":"Roccaro AM, Hideshima T, Richardson PG, et\u00a0al. Bortezomib as an antitumor agent. Current Pharmaceutical Biotechnology. 2006;7:441-448","DOI":"10.2174\/138920106779116865"},{"key":"ref=156","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Richardson P, et\u00a0al. NF-kappa B as a therapeutic target in multiple myeloma. The Journal of Biological Chemistry. 2002;277:16639-16647. DOI: 10.1074\/jbc.M200360200","DOI":"10.1074\/jbc.M200360200"},{"key":"ref=157","doi-asserted-by":"crossref","unstructured":"Gandolfi S, Laubach JP, Hideshima T, et\u00a0al. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Reviews. 2017;36:561-584. DOI: 10.1007\/s10555-017-9707-8","DOI":"10.1007\/s10555-017-9707-8"},{"key":"ref=158","doi-asserted-by":"crossref","unstructured":"Moreau P, Touzeau C.\u00a0Multiple myeloma: From front-line to relapsed therapies. American Society of Clinical Oncology Educational Book. 2015:e504-e511. DOI: 10.14694\/EdBook_AM.2015.35.e504","DOI":"10.14694\/EdBook_AM.2015.35.e504"},{"key":"ref=159","doi-asserted-by":"crossref","unstructured":"Chauhan D, Tian Z, Zhou B, et\u00a0al. In vitro and in\u00a0vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clinical Cancer Research. 2011;17:5311-5321. DOI: 10.1158\/1078-0432.CCR-11-0476","DOI":"10.1158\/1078-0432.CCR-11-0476"},{"key":"ref=160","doi-asserted-by":"crossref","unstructured":"McConkey DJ, Zhu K.\u00a0Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates. 2008;11:164-179. DOI: 10.1016\/j.drup.2008.08.002","DOI":"10.1016\/j.drup.2008.08.002"},{"key":"ref=161","doi-asserted-by":"crossref","unstructured":"Brito AB, Louren\u00e7o GJ, Oliveira GB, et\u00a0al. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Annals of Hematology. 2014;93:1363-1369. DOI: 10.1007\/s00277-014-2062-8","DOI":"10.1007\/s00277-014-2062-8"},{"key":"ref=162","doi-asserted-by":"crossref","unstructured":"Sissung TM, Peer CJ, Korde N, et\u00a0al. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemotherapy and Pharmacology. 2017;80:217-221. DOI: 10.1007\/s00280-017-3323-8","DOI":"10.1007\/s00280-017-3323-8"},{"key":"ref=163","doi-asserted-by":"crossref","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J.\u00a0Thalidomide is an inhibitor of angiogemesis. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:4082-4085","DOI":"10.1073\/pnas.91.9.4082"},{"key":"ref=164","doi-asserted-by":"crossref","unstructured":"Mercurio A, Adriani G, Catalano A, et\u00a0al. A mini-review on thalidomide: Chemistry, mechanisms of action, therapeutic potential and anti-angiogenic properties in multiple myeloma. Current Medicinal Chemistry. 2017;24:2736-2744. DOI: 10.2174\/0929867324666170601074646","DOI":"10.2174\/0929867324666170601074646"},{"key":"ref=165","doi-asserted-by":"crossref","unstructured":"Gao Y, Ma G, Liu S, et\u00a0al. Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in\u00a0vitro. Thrombosis Research. 2015;135:1154-1159. DOI: 10.1016\/j.thromres.2015.03.019","DOI":"10.1016\/j.thromres.2015.03.019"},{"key":"ref=166","doi-asserted-by":"crossref","unstructured":"Ribatti D, Vacca A.\u00a0Novel therapeutic approches targeting vascular endothelial growth factor and its receptors in haematological malignancies. Current Cancer Drug Targets. 2005;5:573-578. DOI: 10.2174\/156800905774932806","DOI":"10.2174\/156800905774932806"},{"key":"ref=167","doi-asserted-by":"crossref","unstructured":"Gupta D, Treon SP, Shima Y, et\u00a0al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factoor secretion: Therapeutic application. Leukemia. 2001;15:1950-1961","DOI":"10.1038\/sj.leu.2402295"},{"key":"ref=168","doi-asserted-by":"crossref","unstructured":"Dredge K, Marriott JB, Macdonald CD, et\u00a0al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer. 2002;87:1166-1172. DOI: 10.1038\/sj.bjc.6600607","DOI":"10.1038\/sj.bjc.6600607"},{"key":"ref=169","doi-asserted-by":"crossref","unstructured":"Bartlett JB, Dredge K, Dalgleish AG.\u00a0The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews. Cancer. 2004;4:314-322. DOI: 10.1038\/nrc1323","DOI":"10.1038\/nrc1323"},{"key":"ref=170","doi-asserted-by":"crossref","unstructured":"De Luisi A, Ferrucci A, Coluccia AM, et\u00a0al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clinical Cancer Research. 2011;17:1935-1946. DOI: 10.1158\/1078-0432.CCR-10-2381","DOI":"10.1158\/1078-0432.CCR-10-2381"},{"key":"ref=171","doi-asserted-by":"crossref","unstructured":"Saini N, Mahindra A.\u00a0Novel immunomodulatory compounds in multiple myeloma. Expert Opinion on Investigational Drugs. 2013;22:207-215. DOI: 10.1517\/13543784.2013.749235","DOI":"10.1517\/13543784.2013.749235"},{"key":"ref=172","doi-asserted-by":"crossref","unstructured":"Mark TM, Coleman M, Niesvizky R.\u00a0Preclinical and clinical results with pomalidomide in the treatment of relapsed\/refractory multiple myeloma. Leukemia Research. 2014 May;38(5):517-524. DOI: 10.1016\/j.leukres.2014.02.008","DOI":"10.1016\/j.leukres.2014.02.008"},{"key":"ref=173","doi-asserted-by":"crossref","unstructured":"Scavelli C, Di Pietro G, Cirulli T, et\u00a0al. Zoledronic acid affects ocer-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Molecular Cancer Therapeutics. 2007;6(12 Pt 1):3256-3262. DOI: 10.1158\/1535-7163.MCT-07-0311","DOI":"10.1158\/1535-7163.MCT-07-0311"},{"key":"ref=174","unstructured":"Ria R, Reale A, Moschetta M, et\u00a0al. A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents. International Journal of Clinical and Experimental Medicine. 2013;6:30-38"},{"key":"ref=175","doi-asserted-by":"crossref","unstructured":"Ribatti D, Nico B, Mangieri D, et\u00a0al. Neridronate inhibits angiogenesis in\u00a0vitro and in\u00a0vivo. Clinical Rheumatology. 2007;26:1094-1098. DOI: 10.1007\/s10067-006-0455-3","DOI":"10.1007\/s10067-006-0455-3"},{"key":"ref=176","doi-asserted-by":"crossref","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W.\u00a0Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews. Drug Discovery. 2004;3:391-400. DOI: 10.1038\/nrd1381","DOI":"10.1038\/nrd1381"},{"key":"ref=177","doi-asserted-by":"crossref","unstructured":"Podar K, Anderson KC.\u00a0The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood. 2005;105:1383-1395. DOI: 10.1182\/blood-2004-07-2909","DOI":"10.1182\/blood-2004-07-2909"},{"key":"ref=178","doi-asserted-by":"crossref","unstructured":"Zagouri F, Terpos E, Kastritis E, Dimopoulos MA.\u00a0Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs. 2016;21:225-237. DOI: 10.1080\/14728214.2016.1186644","DOI":"10.1080\/14728214.2016.1186644"},{"key":"ref=179","doi-asserted-by":"crossref","unstructured":"Cook KM, Figg WD.\u00a0Angiogenesis inhibitors: Current strategies and future prospects. CA: A Cancer Journal for Clinicians. 2010;60:222-243. DOI: 10.3322\/caac.20075","DOI":"10.3322\/caac.20075"},{"key":"ref=180","doi-asserted-by":"crossref","unstructured":"Mo HN, Liu P.\u00a0Targeting MET in cancer therapy. Chronic Diseases and Translational Medicine. 2017;3:148-153. DOI: 10.1016\/j.cdtm.2017.06.002","DOI":"10.1016\/j.cdtm.2017.06.002"},{"key":"ref=181","doi-asserted-by":"crossref","unstructured":"Lopuch S, Kawalec P, Wi\u015bniewska N.\u00a0Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis. Hematology. 2015;20:1-10. DOI: 10.1179\/1607845414Y.0000000159","DOI":"10.1179\/1607845414Y.0000000159"}],"container-title":["Update on Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/61695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T04:13:13Z","timestamp":1573877593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/books\/update-on-multiple-myeloma\/angiogenesis-and-antiangiogenesis-in-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"ISBN":["9781789852172","9781789852189"],"references-count":181,"URL":"https:\/\/doi.org\/10.5772\/intechopen.76931","relation":{},"subject":[],"published":{"date-parts":[[2019,2,20]]}}}